Clinical Trial Update: Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant [Phase 3]

View source ↗

Summary

Phase III trial update evaluating daclatasvir + sofosbuvir + ribavirin in cirrhotic Hepatitis C patients and those post-liver transplant. Results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2015-10-20